The Azygos Esophageal Recess Is Not to Be Missed in Screening Lung Cancer With LDCT.
Journal
Journal of thoracic imaging
ISSN: 1536-0237
Titre abrégé: J Thorac Imaging
Pays: United States
ID NLM: 8606160
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
13
9
2024
Statut:
aheadofprint
Résumé
Lesion overlooking and late diagnostic workup can compromise the efficacy of low-dose CT (LDCT) screening of lung cancer (LC), implying more advanced and less curable disease stages. We hypothesized that the azygos esophageal recess (AER) of the right lower lobe (RLL) might be an area prone to lesion overlooking in LC screening. Two radiologists reviewed the LDCT examinations of all the screen-detected incident LCs observed in the active arm of 2 randomized clinical trials: ITALUNG and national lung screening trial. Those in the AER were compared with those in the remainder of the RLL for possible differences in diagnostic lag according to the Lung-RADS 1.1 recommendations, size, stage, and mortality. Six (11.7%) of 51 screen-detected incident LCs of the RLL were located in the AER. The diagnostic lag time was significantly longer (P=0.046) in the AER LC (mean 14±9 mo) than in the LC in the remaining RLL (mean 7.3±1 mo). Size and stage at diagnosis were not significantly different. All 6 subjects with LC in the AER and 16 (35.5%) of 45 subjects with LC in the remaining RLL (P=0.004) died of LC after a median follow-up of 12 years. Our retrospective study indicates that AER might represent a lung region of the RLL prone to have early LC overlooked due to detection or interpretation errors with possible detrimental consequences for the subject undergoing LC screening.
Identifiants
pubmed: 39267479
doi: 10.1097/RTI.0000000000000813
pii: 00005382-990000000-00151
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ravenel JG, Erasmus JJ. Azygoesophageal recess. J Thor Imaging. 2002;17:219–226.
Gibbs JM, Chandrasekhar CA, Ferguson EC, et al. Lines and stripes: where did they go?—from conventional radiography to CT. RadioGraphics. 2007;27:33–48.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;7:209–249.
Krist AH, Davidson KW, et alUS Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:962–970.
Aberle DR, Adams AM, et alNational Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur. 2021;10:100179.
Horeweg N, Scholten ET, de Jong PA, et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol. 2014;15:1342–1350.
Scholten ET, Horeweg N, de Koning HJ, et al. Computed tomographic characteristics of interval and post screen carcinomas in lung cancer screening. Eur Radiol. 2015;25:81–88.
Gierada DS, Pinsky PF, Duan F, et al. Interval lung cancer after a negative CT screening examination: CT findings and outcomes in National Lung Screening Trial participants. Eur Radiol. 2017;27:3249–3256.
Bartlett EC, Silva M, Callister ME, et al. False-negative results in lung cancer screening-evidence and controversies. J Thorac Oncol. 2021;16:912–921.
Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomized lung cancer screening trial. Thorax. 2017;72:825–831.
Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2009;64:34–40.
Lopes Pegna A, Picozzi G, Falaschi F, et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol. 2013;8:866–875.
Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013;369:920–931.
Puliti D, Mascalchi M, Carozzi MF, et al. Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: analysis of the underlying factors. Lung Cancer. 2019;138:72–78.
National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019;14:1732–1742.
Mascalchi M, Attinà D, Bertelli E, et al. Lung cancer associated with cystic airspaces. J Comput Assist Tomogr. 2015;39:102–108.
Silva M, Picozzi G, Sverzellati N, et al. Low-dose CT for lung cancer screening: position paper from the Italian college of thoracic radiology. Radiol Med. 2022;127:543–559.
Martin MD, Kanne JP, Broderick LS, et al. RadioGraphics update: Lung-RADS 2022. Radiographics. 2023;43:e230037.
Mao Y, Cai J, Heuvelmans MA, et al. Performance of Lung-RADS in different target populations: a systematic review and meta-analysis. Eur Radiol. 2024;34:1877–1892.
Cai J, Xu D, Liu S, et al. The Added Value of Computer-aided detection of small pulmonary nodules and missed lung cancers. J Thorac Imaging. 2018;33:390–395.
Huang P, Park S, Yan R, et al. Added value of computer-aided CT image features for early lLung cancer diagnosis with small pulmonary nodules: a matched case-control study. Radiology. 2018;286:286–295.